Skip Navigation


Annals of Oncology Advance Access originally published online on December 20, 2007
Annals of Oncology 2008 19(2):370-373; doi:10.1093/annonc/mdm501
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/2/370    most recent
mdm501v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Castagneto, B.
Right arrow Articles by Mencoboni, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Castagneto, B.
Right arrow Articles by Mencoboni, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology. For Permissions, please email: journals.permissions@oxfordjournals.org

lung cancer

Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM)

B. Castagneto1, M. Botta1, E. Aitini2, F. Spigno7, D. Degiovanni1, O. Alabiso4, M. Serra3, A. Muzio1, R. Carbone5, R. Buosi4, V. Galbusera3, E. Piccolini6, L. Giaretto1, L. Rebella3 and M. Mencoboni3,*

1 Department of Oncology, Novi Ligure Hospital, viale Giolitti, Novi Ligure (AL)
2 Department of Oncology, Ospedale ‘C. Poma’, viale Albertoni, Mantova
3 Department of Oncology, Ospedale ‘Villa Scassi’, Corso Onofrio Scassi, Genova
4 Department of Oncology, Ospedale Maggiore della Carità, Corso Mazzini, Novara
5 Department of Pneumology, Ospedale Regionale di Aosta, viale Ginevra, Aosta
6 Department of Pneumology, Ospedale ‘S. Spirito’, viale Giolitti, Casale Monferrato (AL)
7 Occupational Medicine Unit, University of Genoa, Largo Rosanna Benzi, Genova, Italy

* Correspondence to: Dr M. Mencoboni, via Giovanni Torti 6/13, 16143 Genoa, Italy. Tel: +39-010-4102639; Fax: +39-010-8630625; E-mail: manlio.mencoboni{at}fastwebnet.it

Background: The aim of this study was to evaluate the activity and toxicity of pemetrexed and carboplatin combination as first-line chemotherapy in malignant pleural mesothelioma (MPM).

Patients and methods: Patients with measurable advanced MPM and a zero to two Eastern Cooperative Oncology Group (ECOG) performance status (PS) were enrolled. The schedule was pemetrexed 500 mg/m2 in combination with carboplatin area under the curve 5, every 21 days. In all, 76 patients were treated. Median age was 65 years; median ECOG PS was zero.

Results: Grade 3 hematological toxicity according to World Health Organization criteria was seen in 36 (47.3%) patients; grade 4 hematological toxicity in 5 (6.5%) patients. There were 16 (21%) partial responses and 3 (4%) complete responses, for an overall response rate of 19 (25%) [95% confidence interval (CI) 15.3–34.7]. In all, 29 (39%) (95% CI 28–48) patients reported stable disease. The median survival was estimated at 14 months.

Conclusion: This combination of carboplatin and pemetrexed is moderately active and the toxicity is acceptable.

Key words: chemotherapy, mesothelioma, pemetrexed

Received for publication June 2, 2007. Revision received September 12, 2007. Accepted for publication September 14, 2007.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.